Sign In
Buy EYEN
$7.56
+0 (+0%)
At Close: Jan 16, 2026
Brookline Capital Management Equities Analysts Boost Earnings Estimates for Eyenovia, Inc. (NASDAQ:EYEN)
01:38am, Monday, 20'th May 2024
Eyenovia, Inc. (NASDAQ:EYEN – Free Report) – Equities research analysts at Brookline Capital Management boosted their Q2 2024 earnings per share (EPS) estimates for Eyenovia in a research
Q2 2024 EPS Estimates for Eyenovia, Inc. (NASDAQ:EYEN) Lowered by HC Wainwright
01:38am, Monday, 20'th May 2024
Eyenovia, Inc. (NASDAQ:EYEN – Free Report) – Equities researchers at HC Wainwright decreased their Q2 2024 EPS estimates for shares of Eyenovia in a research report issued to clients and i
Eyenovia, Inc. (EYEN) Q1 2024 Earnings Call Transcript
09:12pm, Friday, 17'th May 2024
Eyenovia, Inc. (NASDAQ:EYEN ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Offic
Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
07:00am, Tuesday, 14'th May 2024
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
07:00am, Thursday, 25'th Apr 2024
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye)
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
10:31am, Tuesday, 09'th Apr 2024
Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its plans for accelerating development of its potential multi-billion
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
07:00am, Wednesday, 03'rd Apr 2024
Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting,
Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript
08:52pm, Monday, 18'th Mar 2024
Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
06:21pm, Monday, 18'th Mar 2024
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
04:05pm, Monday, 18'th Mar 2024
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
07:00am, Wednesday, 13'th Mar 2024
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreeme
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
07:00am, Monday, 11'th Mar 2024
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery
